Drug Trial Radar · NCT06267729
Study of AZD0754 in Participants With Metastatic Prostate Cancer
Last checked: Nov 19, 2026Latest source record: Feb 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Mar 12, 2024
Primary completion
Nov 24, 2026
Study completion Nov 24, 2026
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Feb 20, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years, up to 130 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety, tolerability, and antitumour activity of AZD0754 CAR T-cell therapy in participants with metastatic prostate cancer.
Conditions
- Metastatic Prostate Cancer
Interventions
AZD0754Biological
Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) to produce AZD0754. During AZD0754 production, subjects may receive bridging therapy for disease control. Upon successful generation of AZD0754 product, subjects will receive treatment with AZD0754 therapy. Study treatment will include lymphodepleting chemotherapy. After lymphodepleting chemotherapy AZD0754 is administered intravenously and patients will be required to stay at the hospital for a protocol specified monitoring period.
AZD2287Biological
This is an Optional arm of the study, which subjects will separately consent to if they would like to participate. Subjects will receive doses of a radioactive imaging agent called AZD2287 followed by SPECT/CT imaging scans at two time points.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of participants with Dose-limiting Toxicity (DLTs)/DLT-like events, Adverse Events (AEs), including Adverse Events of Special Interest (AESIs) and Serious Adverse Events (SAEs).Time frame: Through study completion, an average of 2 years
Locations
15 sites in 3 countries. Site status is shown where the registry gives one.
Research Site
Duarte, California · Recruiting
Research Site
Tampa, Florida · Recruiting
Research Site
Atlanta, Georgia · Recruiting
Research Site
Westwood, Kansas · Not yet recruiting
Research Site
Boston, Massachusetts · Not yet recruiting
Research Site
Boston, Massachusetts · Not yet recruiting
Research Site
St Louis, Missouri · Recruiting
Research Site
Hackensack, New Jersey · Recruiting
Research Site
New York, New York · Recruiting
Research Site
New York, New York · Recruiting
Research Site
Philadelphia, Pennsylvania · Recruiting
Research Site
Dallas, Texas · Not yet recruiting
Research Site
Houston, Texas · Recruiting
Research Site
East Melbourne, Australia · Recruiting
Research Site
Pamplona, Spain · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.